Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has reported its second-quarter results for 2025, showcasing significant progress in its oncology drug development programs and the expansion of its artificial intelligence (AI) platform, RADR(R). The company announced complete responses in patients participating in two of its clinical trials: LP-300 for advanced non-small cell lung cancer (NSCLC) and LP-284 for refractory diffuse large B-cell lymphoma. Additionally, Lantern Pharma has completed the enrollment for the Phase 1a study of LP-184, setting the stage for Phase 1b/2 studies in high-value indications. LP-184 has been granted FDA Fast Track designation and multiple Rare Pediatric Disease designations, demonstrating significant survival benefits in atypical teratoid rhabdoid tumor (ATRT) models.
In a strategic move to bolster its intellectual property, Lantern Pharma secured a European patent allowance for LP-284 and published a Patent Cooperation Treaty (PCT) application for its predictBBB(TM) AI module. The company also unveiled enhancements to its RADR(R) platform, including the public launch of predictBBB.ai(TM) and the introduction of a new drug combination prediction module. These advancements underscore Lantern Pharma's commitment to leveraging AI and machine learning to revolutionize oncology drug discovery and development.
Financially, Lantern Pharma reported a reduction in Q2 2025 R&D expenses to $3.1 million from $3.9 million in the previous year, while G&A expenses slightly increased to $1.6 million from $1.5 million. The company's net loss narrowed to $4.33 million from $4.96 million, reflecting improved operational efficiency. With cash, equivalents, and marketable securities totaling $15.9 million at the end of the quarter, Lantern Pharma is well-positioned to fund its operations into June 2026.
The implications of Lantern Pharma's Q2 achievements are profound for the oncology and biopharmaceutical industries. The complete responses in clinical trials and the expansion of the RADR(R) platform highlight the potential of AI to accelerate drug discovery, reduce costs, and improve patient outcomes. For more details on Lantern Pharma's Q2 2025 results and portfolio updates, visit https://ibn.fm/VD5Ik.
